Samsung Bioepis, C-Bridge Capital to develop and commercialize next-generation biosimilars in China

Image: Samsung Bioepis and C-Bridge Capital will develop and commercialize next-generation biosimilars in China. Photo: courtesy of freebieshutterb / FreeDigitalPhotos.net.